Skip to main content

dividend aristocrat

6 articles found

XOM: Oil Surge Pushes Exxon to 52-Week Highs

Exxon Mobil (XOM) is trading at $155.21 — within striking distance of its 52-week high of $159.35 — as geopolitical turmoil in the Middle East sends oil prices surging. The $647 billion energy giant has climbed nearly 8% in a week, fueled by the Iran conflict's disruption of Qatar's LNG output and escalating military operations that have rattled global energy supply chains. The rally comes at an interesting juncture for Exxon. While 2025 was a year of declining earnings compared to 2024 — net income fell 14% to $28.8 billion as oil prices moderated — the company's operational execution remained strong. Record upstream production volumes, disciplined capital allocation, and $37.5 billion returned to shareholders through buybacks and dividends demonstrate a business firing on all cylinders even in a softer commodity environment. Now, with crude oil surging past $80 on supply disruption fears, investors face a key question: is Exxon's rally sustainable, or is geopolitical premium masking a weaker earnings trajectory?

XOMExxon Mobiloil stocks

ABBV: Dividend Aristocrat With Hidden Earnings

AbbVie Inc. (NYSE: ABBV) closed at $232.03 on February 28, 2026, up 3.27% on the session and commanding a market capitalization of $410.1 billion. The stock has rallied 41% from its 52-week low of $164.39 and now trades just 5% below its 52-week high of $244.81, comfortably above both its 50-day moving average of $224.13 and 200-day moving average of $212.09. The headline that stops most investors cold is the trailing P/E ratio of 98.7x. On its face, that looks absurd for a mature pharmaceutical company. But the GAAP earnings figure driving that ratio — just $2.35 per share over the trailing twelve months — is distorted by billions in non-cash amortization from AbbVie's $63 billion Allergan acquisition in 2020. Adjusted earnings tell a radically different story, and analyst estimates for 2027 suggest the gap between reported and economic earnings is about to narrow sharply. Q4 2025 revenue of $16.618 billion marked the strongest quarter in company history, capping a full year at approximately $61.16 billion. With Rinvoq and Skyrizi now firmly replacing lost Humira revenue, AbbVie has earned recognition as both a Dividend Aristocrat and, increasingly, a value stock hiding in plain sight behind acquisition accounting.

AbbVieABBV stockAbbVie stock analysis

XOM: ExxonMobil's $621 Billion Energy Empire Rallies 50%

Exxon Mobil Corporation (NYSE: XOM) has staged one of the most impressive rallies in the energy sector, surging roughly 50% from its May 2025 low of $97.80 to trade at $147.28 as of February 21, 2026. The world's largest publicly traded oil company now commands a market capitalisation of $621 billion, making it the undisputed heavyweight of Western energy. With 43 consecutive years of dividend increases and $52 billion in annual operating cash flow, ExxonMobil remains a cornerstone holding for income-focused investors. Yet the headline numbers mask a more nuanced picture. Fourth-quarter 2025 results revealed meaningful margin compression, with operating income dropping to 7.5% of revenue — roughly half the rate posted in Q1. Full-year net income fell to $28.8 billion from $33.7 billion in 2024, while free cash flow declined to $23.6 billion from $30.7 billion. At 22 times trailing earnings, XOM is no longer the deep-value play it was nine months ago. The question for investors is whether the company's production growth, carbon capture investments, and capital discipline can justify a premium multiple in a normalising energy market.

XOMExxonMobilstock analysis

PG: Procter & Gamble's $376 Billion Consumer Staples Empire

Procter & Gamble (NYSE: PG) is the kind of company that thrives in the background of everyday life. From Tide laundry detergent and Gillette razors to Pampers diapers and Oral-B toothbrushes, the Cincinnati-based consumer goods giant touches roughly five billion consumers worldwide across 180 countries. At $160.78 per share and a $376 billion market capitalisation, PG trades at 23.8x trailing earnings — a premium valuation, but one that has historically been justified by the company's relentless cash generation and pricing power. The stock has rallied 17% from its 52-week low of $137.62, though it remains roughly 11% below its $179.99 high. That gap is notable because PG just delivered its fiscal Q2 2026 results showing $22.2 billion in revenue, a 51.2% gross margin, and diluted EPS of $1.78. The company also presented at the prestigious Consumer Analyst Group of New York (CAGNY) conference this week, reaffirming its commitment to organic growth through innovation and productivity. For income investors, PG remains a Dividend Aristocrat with 69 consecutive years of dividend increases — one of the longest streaks in the S&P 500. The current yield of approximately 2.5% may seem modest, but coupled with consistent buybacks and mid-single-digit earnings growth, total shareholder returns have compounded reliably for decades. The question now is whether the stock's premium multiple still offers adequate upside, or whether tariff headwinds and currency pressures will compress returns from here.

Procter & GamblePG stock analysisconsumer staples

MCD: McDonald's $235 Billion Franchise Empire Nears Its

McDonald's Corporation (NYSE: MCD) is trading at $329.23, just 2% below its 52-week high of $335.67, after a sustained rally that has carried the stock 16% above its 52-week low of $283.47. The golden arches sit atop a $235 billion market capitalisation and one of the most envied business models in corporate America — a franchise-heavy, asset-light operation that converts hamburgers into a $10.6 billion annual cash flow machine. Full-year 2025 results, reported on February 11, tell a story of steady execution: $26.9 billion in revenue, $8.6 billion in net income, and diluted EPS of $11.95. McDonald's also announced its 50th consecutive annual dividend increase, cementing its status as a Dividend Aristocrat. But with the stock trading at 27.5x trailing earnings and total debt exceeding $68 billion, investors need to ask whether the price already reflects perfection — or whether McDonald's durable competitive advantages justify the premium. The answer depends on how you value predictability. Few companies on earth generate cash as reliably as McDonald's, and even fewer return virtually all of it to shareholders. For patient, income-oriented investors, this remains one of the most compelling compounders in the market. For value hunters, the current multiple demands scrutiny.

McDonald's stock analysisMCD stockMcDonald's dividend

KO Analysis: 64 Years of Dividend Hikes and a 15% YTD Rally

The Coca-Cola Company (NYSE: KO) is trading at $78.91, just 1.9% below its 52-week high of $80.41 and up roughly 15% year-to-date in 2026. The beverage giant, with a market capitalization of $339.4 billion, continues to command one of the most recognizable brand portfolios on the planet — spanning Coca-Cola, Sprite, Fanta, Minute Maid, Costa Coffee, and more than 200 other brands sold in over 200 countries. The company just delivered its fiscal year 2025 results on February 10, and the board followed up on February 19 with its 64th consecutive annual dividend increase — raising the quarterly payout approximately 4% to $0.53 per share, or $2.12 annualized. That kind of consistency is why KO remains a cornerstone holding for income-focused portfolios and a fixture in Warren Buffett's Berkshire Hathaway. But the stock's sharp rally has compressed its value proposition considerably. Benzinga's value score dropped from 17.86 to just 3.28 in a single week following the Q4 earnings report. With trailing PE at nearly 26x, a tepid 2026 outlook, and free cash flow that declined significantly in 2025, the question facing investors is clear: Is Coca-Cola's bulletproof brand worth paying a premium for, or has the market gotten ahead of the fundamentals?

Coca-ColaKOdividend aristocrat